<?xml version="1.0" encoding="UTF-8"?>
<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <act name="AS">
    <meta>
      <identification source="#arch">
        <FRBRWork>
          <FRBRthis value="/akn/us-ak/act/as/title-11/chapter-73"/>
          <FRBRuri value="/akn/us-ak/act/as/title-11/chapter-73"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#alaska-legislature"/>
          <FRBRcountry value="us-ak"/>
          <FRBRnumber value="11.73"/>
          <FRBRname value="AS"/>
        </FRBRWork>
        <FRBRExpression>
          <FRBRthis value="/akn/us-ak/act/as/title-11/chapter-73/eng@2025-12-31"/>
          <FRBRuri value="/akn/us-ak/act/as/title-11/chapter-73/eng@2025-12-31"/>
          <FRBRdate date="2025-12-31" name="publication"/>
          <FRBRauthor href="#arch"/>
          <FRBRlanguage language="eng"/>
        </FRBRExpression>
        <FRBRManifestation>
          <FRBRthis value="/akn/us-ak/act/as/title-11/chapter-73/eng@2025-12-31/main.xml"/>
          <FRBRuri value="/akn/us-ak/act/as/title-11/chapter-73/eng@2025-12-31/main.xml"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#arch"/>
        </FRBRManifestation>
      </identification>
      <references source="#arch">
        <TLCOrganization eId="arch" href="https://cosilico.ai" showAs="Cosilico Arch"/>
        <TLCOrganization eId="alaska-legislature" href="https://www.akleg.gov" showAs="Alaska State Legislature"/>
      </references>
    </meta>
    <body>
      <title eId="title_11">
        <num>11</num>
        <heading>Criminal Law</heading>
        <chapter eId="title_11__chp_73">
          <num>73</num>
          <heading>Imitation Controlled Substances</heading>
          <section eId="sec_11-73-010">
            <num>11.73.010</num>
            <heading>Manufacture or delivery of an imitation controlled substance.</heading>
            <subsection eId="11-73-010__subsec_a">
              <num>(a)</num>
              <content>
                <p>Except as provided in
AS 11.73.050
, a person may not manufacture, deliver, or possess with intent to deliver, an imitation controlled substance.</p>
              </content>
            </subsection>
            <subsection eId="11-73-010__subsec_b">
              <num>(b)</num>
              <content>
                <p>Except as provided in
AS 11.73.030
, a person who violates this section commits a class C felony.</p>
              </content>
            </subsection>
          </section>
          <section eId="sec_11-73-020">
            <num>11.73.020</num>
            <heading>Possession of substance with intent to manufacture.</heading>
            <subsection eId="11-73-020__subsec_a">
              <num>(a)</num>
              <content>
                <p>Except as provided in
AS 11.73.050
, a person may not possess the following substances or their salts with the intent to manufacture an imitation controlled substance:</p>
              </content>
              <paragraph eId="11-73-020__subsec_a__subsec_1">
                <num>(1)</num>
                <content>
                  <p>ephedrine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_2">
                <num>(2)</num>
                <content>
                  <p>ephedrine sulfate;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_3">
                <num>(3)</num>
                <content>
                  <p>pseudoephedrine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_4">
                <num>(4)</num>
                <content>
                  <p>pseudoephedrine hydrochloride;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_5">
                <num>(5)</num>
                <content>
                  <p>phenylpropanolamine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_6">
                <num>(6)</num>
                <content>
                  <p>caffeine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_7">
                <num>(7)</num>
                <content>
                  <p>theophylline;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_8">
                <num>(8)</num>
                <content>
                  <p>lidocaine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_9">
                <num>(9)</num>
                <content>
                  <p>procaine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_10">
                <num>(10)</num>
                <content>
                  <p>tetracaine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_11">
                <num>(11)</num>
                <content>
                  <p>dyclonine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_12">
                <num>(12)</num>
                <content>
                  <p>acetaminophen;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_13">
                <num>(13)</num>
                <content>
                  <p>salicylamide;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_14">
                <num>(14)</num>
                <content>
                  <p>doxylamine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_15">
                <num>(15)</num>
                <content>
                  <p>diphenhydramine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_16">
                <num>(16)</num>
                <content>
                  <p>pheniramine;</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_17">
                <num>(17)</num>
                <content>
                  <p>chlorpheniramine; or</p>
                </content>
              </paragraph>
              <paragraph eId="11-73-020__subsec_a__subsec_18">
                <num>(18)</num>
                <content>
                  <p>pyrilamine.</p>
                </content>
              </paragraph>
            </subsection>
            <subsection eId="11-73-020__subsec_b">
              <num>(b)</num>
              <content>
                <p>A person who violates this section commits a class C felony.</p>
              </content>
            </subsection>
          </section>
          <section eId="sec_11-73-030">
            <num>11.73.030</num>
            <heading>Delivery of an imitation controlled substance to a minor.</heading>
            <subsection eId="11-73-030__subsec_a">
              <num>(a)</num>
              <content>
                <p>Except as provided in
AS 11.73.050
, a person 19 years of age or older may not deliver an imitation controlled substance to a person under 19 years of age, who is at least three years younger than the person delivering the substance.</p>
              </content>
            </subsection>
            <subsection eId="11-73-030__subsec_b">
              <num>(b)</num>
              <content>
                <p>A person who violates this section commits a class B felony.</p>
              </content>
            </subsection>
          </section>
          <section eId="sec_11-73-040">
            <num>11.73.040</num>
            <heading>Advertisement to promote the delivery of an imitation controlled substance.</heading>
            <subsection eId="11-73-040__subsec_a">
              <num>(a)</num>
              <content>
                <p>Except as provided in
AS 11.73.050
, a person may not knowingly place in a newspaper, magazine, handbill, or other publication, or post or distribute in a public place, an advertisement or solicitation knowing that the purpose of the advertisement or solicitation is to promote the delivery of an imitation controlled substance in the state.</p>
              </content>
            </subsection>
            <subsection eId="11-73-040__subsec_b">
              <num>(b)</num>
              <content>
                <p>A person who violates this section commits a class C felony.</p>
              </content>
            </subsection>
          </section>
          <section eId="sec_11-73-050">
            <num>11.73.050</num>
            <heading>Imitation controlled substance as placebo.</heading>
            <content>
              <p>Sec. 11.73.050.   Imitation controlled substance as placebo.
No civil or criminal liability may be imposed under this chapter on a person who manufactures, delivers, possesses, or advertises or solicits to promote delivery of an imitation controlled substance solely for use as a placebo prescribed by a registered practitioner, as defined in
AS 11.71.900
, in the course of professional practice or research.</p>
            </content>
          </section>
          <section eId="sec_11-73-060">
            <num>11.73.060</num>
            <heading>Forfeitures.</heading>
            <subsection eId="11-73-060__subsec_a">
              <num>(a)</num>
              <content>
                <p>Property used during or in aid of a violation of this chapter may be forfeited to the state to the extent permitted under and in accordance with the provisions of
AS 17.30.110
 17.30.126.</p>
              </content>
            </subsection>
            <subsection eId="11-73-060__subsec_b">
              <num>(b)</num>
              <content>
                <p>For purposes of this section the terms controlled substance and this chapter, as used in
AS 17.30.110
 17.30.126, shall be construed as imitation controlled substance and 
AS 11.73
 respectively.</p>
              </content>
            </subsection>
          </section>
          <section eId="sec_11-73-099">
            <num>11.73.099</num>
            <heading>Definitions.</heading>
            <content>
              <p>Sec. 11.73.099.   Definitions.
In this chapter,
(1) controlled substance means a substance as defined in
AS 11.71.900
(5);
(2) deliver or delivery means the actual, constructive, or attempted transfer from one person to another of an imitation controlled substance, whether or not there is an agency relationship;
(3) imitation controlled substance means a substance containing ephedrine, ephedrine sulfate, pseudoephedrine, pseudoephedrine hydrochloride, phenylpropanolamine, caffeine, theophylline, lidocaine, procaine, tetracaine, dyclonine, acetaminophen, salicylamide, doxylamine, diphenhydramine, pheniramine, chlorpheniramine, or pyrilamine, or their salts, that is not a controlled substance, and that by dosage unit appearance (including color, shape, size, and markings) and by representations would lead a reasonable person to believe that the substance is a controlled substance; the term representations, as used in this paragraph, includes
(A) statements made by an owner or by anyone else in control of the substance concerning the nature of the substance, or its use or effect;
(B) statements made to the recipient that the substance may be resold for inordinate profit;
(C) whether the substance is packaged in a manner normally used for controlled substances;
(D) evasive tactics or actions used by the owner or person in control of the substance to avoid detection by law enforcement authorities;
(E) the storage, packaging, presentation, display of, or reference to a controlled substance with, near, or in connection with the activity involving the imitation controlled substance;
(4) manufacture means the production, preparation, compounding, processing, encapsulating, packaging or repackaging, labeling or relabeling, of an imitation controlled substance.</p>
            </content>
          </section>
        </chapter>
      </title>
    </body>
  </act>
</akomaNtoso>